ISSN: 2161-0681

Journal de pathologie clinique et expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • JournalTOC
  • Annuaire des périodiques d'Ulrich
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

The Development of Autoimmune Membrano-Proliferative Glomerulonephritis (Type II) In a Female Patient with Serological Combined Autoantibodies against Complement 3b and Factor B: Case Report

Rudolph B and Wu KY

Background: Most of membranoproliferative glomerulonephritis (MPGN) raise from the abnormalities in alternative complement pathways.

Case presentation: A 3-year-old girl manifested hematuria (HU), proteinuria (PU), and hypocomplementemia (HC) without a known cause; the first renal biopsy indicated MPGN that resembled type I MPGN. After treatment with Methylprednisolone and Cyclophosphamide (CTx), the nephritic syndrome (HU plus PU) withdrew but often relapsed. At the age of 7 years, the clinical situation suddenly worsened, PU and the activity of the urinary sediment increased, and the glomerular filtration rate rapidly decreased; simultaneously, auto-antibodies against Complement 3b (C3b) and Factor B were detected with high titers. The second renal biopsy exhibited a typical glomerular injury of type II MPGN with diffuse cellular crescents; the patient was treated with methylprednisolone plus plasmapheresis and Rituximab, but the renal failure still proceeded. She started peritoneal dialysis at the age of 9 years and received renal transplantation at the age of 11 years; after transplantation, she was given routine immunosuppression plus plasmapheresis and Rituximab (anti-CD 20 globulin), and presented clinical remission except for persistent HC. The nephritic syndrome relapsed at the age of 13 years, and the third renal biopsy confirmed a recurrence of type II MPGN; thereafter, Eculizumab (anti-C5 monoclonal antibody) was administered, which significantly ameliorated the clinical condition.

Conclusion: The pathological appearance of type II MPGN may be variable but not completely irrelevant according to the clinical conditions at the time of biopsy